Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 +0.31%79 Cash Ratio is 1.38 as of Jun. 2026, which is 48% above its 10-year median of 0.93. GuruFocus rates TPE:1733 with a GF Score™ of 79/100 and a GF Value™ of NT$30.00 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,383 Biotechnology companies, Apex Biotechnology ranks worse than 66.67% on this metric.
Apex Biotechnology has a Cash Ratio of 1.38. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Apex Biotechnology's Cash Ratio or its related term are showing as below:
TPE:1733'
s Cash Ratio Range Over the Past 10 Years
Min: 0.59 Med: 0.93 Max: 1.49
Current: 1.38
During the past 13 years, Apex Biotechnology's highest Cash Ratio was 1.49. The lowest was 0.59. And the median was 0.93.
TPE:1733's Cash Ratio is ranked worse than 66.67% of 1383
companies
in the Biotechnology industry
Industry Median: 2.94
vs TPE:1733: 1.38
Apex Biotechnology (TPE:1733) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Apex Biotechnology Cash Ratio Related Terms
Apex Biotechnology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Apex Biotechnology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Cash Ratio of 1.38 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Apex Biotechnology and its competitors. This is 48% above median its historical median of 0.93. Over the past decade, Apex Biotechnology's Cash Ratio has ranged from 0.59 to 1.49. According to the industry distribution chart, Apex Biotechnology ranks #922 out of 1383 companies in the Biotechnology industry, placing it in the top 66.7%.
Is Apex Biotechnology's Cash Ratio too high?
Apex Biotechnology's current Cash Ratio of 1.38 is 48% above median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.49. The Biotechnology industry median Cash Ratio is 2.94. Apex Biotechnology's value of 1.38 is 53.1% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #922 out of 1383 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #922 out of 1383 companies for Cash Ratio. This places Apex Biotechnology in the lower half of its industry. The industry median Cash Ratio is 2.94. Apex Biotechnology's value of 1.38 is 53.1% below this benchmark. Historically, Apex Biotechnology's own Cash Ratio has ranged from 0.59 to 1.49 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 2.94, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Cash Ratio of 1.38 is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Cash Ratio is 1.38, which is 48% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.00, compared to a current price of NT$32.35 — trading 7.8% above its estimated fair value. The current Cash Ratio is 1.38, which is 48% above median its 10-year median of 0.93 and 53.1% below the Biotechnology industry median of 2.94. Apex Biotechnology's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Cash Ratio is 1.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$32.35 is trading 7.8% above its estimated GF Value™ of NT$30.00.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Cash Ratio: 1.38 (48% above median its 10-year median of 0.93)
GF Value™: NT$30.00 vs. price of NT$32.35 (7.8% above fair value)
Industry Position: 53.1% below the Biotechnology median (#922 of 1383)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
79GF Score
Get the complete analysis for TPE:1733
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
